BioVaxys Technology Corp. is a clinical stage biotechnology company. It engages in developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The firm is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology and is preparing for a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for Stage III/Stage IV ovarian cancer. The company was founded by James Christopher Passin, Kenneth E. Kovan and David Berd on April 25, 2018 and is headquartered in Etobicoke, Canada.
Sector:
Non Energy Minerals
Industry:
Other Metals Or Minerals
Employees:
N/A
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. BioVaxys Technology Corp market cap is $3.92M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. BioVaxys Technology Corp 52 week high is $0.203 as of November 20, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. BioVaxys Technology Corp 52 week low is $0.0102 as of November 20, 2026.
BioVaxys Technology Corp stock price today is $0.09.
BioVaxys Technology Corp stock price yesterday was $0.089.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. BioVaxys Technology Corp 50-day moving average is $0.0917.